Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Fondazione Centro San Raffaele Del Monte Tabor

Lusso, Paolo

Paolo Lusso

Mauro Malnati

Francesca Salvatori

Simona Polo

Vincenzo Pavone

Peng Zhang

Leonid Margolis

Raffaello Cimbro

Giulia Cassina

Jean-Charles Grivel

Giuseppe Locatelli

Gabriella Scarlatti

Embodiments of HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. Nucleic acid molecules encoding the HIV-1 Env ectodomain trimers are also provided. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

Recombinant HIV-1 envelope proteins and their use

HIV neutralizing peptides, sulfated HIV-1 envelope proteins and immunogenic fragments thereof are disclosed, as well as nucleic acids encoding these molecules and methods of producing these peptides, envelope proteins and fragments. Methods are also provided for the treatment or prevention of a human immunodeficiency type 1 (HIV-1 ) infection. The methods can include administering to a subject an HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment thereof as disclosed herein. In several embodiments, administering the HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment generates an immune response in a subject.

HIV therapeutics and methods of making and using same

Provided herein is a method for the quantitative detection of HHV-6 subtypes A and/or B based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5'-3&#x2032; nuclease activity.

Method for the quantitative detection of nucleic acids

It has been discovered that herpesviruses can trigger an increase in the production of HIV-suppressive chemokines, and that these chemokines block the CCR5 receptor, which is used as a co-receptor with CD4 in the CCR5-tropic forms of HIV-1 that predominate in early stage HIV-1 infection. Use of live, attenuated or killed herpesviruses, or of herpesvirus proteins which trigger an increase in production of HIV-suppressive chemokines, or of nucleic acids encoding those proteins, can likewise be used to prevent establishment of HIV-1 infection or to inhibit HIV-1 replication. The invention provides uses, methods and compositions related to these discoveries.

Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication

Provided herein is a method for the quantitative detection of nucleic acids based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5'-3&#x2032; nuclease activity.

RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.

RANTES mutants and therapeutic applications thereof

Peptides having 12 to 30 amino acids with sequence homologous or corresponding to the sequence 1o-34 of RANTES having inhibitory activity against the human immunodeficiency virus (HIV) as well as anti-allergic and antiinflamatory activity.

RANTES derived peptides with anti-HIV activity

RANTES mutants characterized by the substitution or addition of amino acids at the N-terminal or RANTES wild-type sequence and in the N loop and/or 40&prime; loop regions of RNATES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.

Growing community of inventors

Milan, Italy

Paolo Lusso